Artis BioSolutions To Acquire Syngoi Technologies

Artis BioSolutions Acquires Landmark Bio

April 2, 2025

Biotechnology

Artis BioSolutions, a newly launched CDMO backed by Oak HC/FT, has acquired Landmark Bio to expand capabilities for the development and manufacturing of cell and gene therapies. Landmark Bio will continue to operate as a distinct entity from its Watertown, Massachusetts headquarters while leveraging Artis' funding and platform to scale process development, GMP manufacturing, and commercialization support.

Standard BioTools Acquires Sengenics from Summa Equity

November 21, 2024

Biotechnology

Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.

Sartorius Stedim Biotech Acquires Polyplus

April 13, 2023

Biotechnology

Sartorius Stedim Biotech agreed to acquire Strasbourg-based Polyplus (Polyplus‑transfection S.A.) for €2.4 billion, pending customary regulatory approvals. The transaction buys the business from private equity backers including ARCHIMED and Warburg Pincus and strengthens Sartorius’s cell & gene therapy reagent and upstream bioprocessing portfolio.

Bionano Genomics Acquires Purigen Biosystems

November 28, 2022

Biotechnology

Bionano Genomics agreed to acquire Purigen Biosystems to integrate Purigen's isotachophoresis (ITP) Ionic Purification System into Bionano's optical genome mapping (OGM) workflow, aiming to simplify ultra-high molecular weight (UHMW) DNA isolation and address difficult sample types. The deal consideration is up to $64 million (including $32 million cash at closing and milestone-contingent payments) and was expected to close by December 8, 2022.

Ginkgo Bioworks to Acquire Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.

Repligen Corporation Acquires ARTeSYN Biosolutions for $200M

October 28, 2020

Medical Devices

Repligen Corporation has agreed to acquire privately-held ARTeSYN Biosolutions for approximately $200 million (about $130 million cash and $70 million in Repligen stock). The purchase expands Repligen's single-use downstream bioprocessing systems portfolio — ARTeSYN was projected to generate roughly $30 million in pro forma 2020 revenue and the deal complements Repligen's recent EMT and NMS acquisitions.